Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
By 18 months after discontinuation, most patients have returned to their baseline weight, erasing the majority of their progress
Phase 2 trials demonstrated A1C reductions of up to 2.02% in participants with type 2 diabetes, bringing average levels from 8.1% down to 6.08%
The American College of Obstetricians and Gynecologists, Breastfeeding Your Baby: Frequently Asked Questions, July 2023 The American College of Obstetricians and Gynecologists, Exercise After Pregnancy, October 2024 The American College of Obstetricians and Gynecologists, Weight Gain During Pregnancy, June 2013 Cleveland Clinic, GLP-1 Agonists, July 2023 Cleveland Clinic, Progestin, March 2023 Current Obesity Reports, Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over, June 2017 Diabetes Care (American Diabetes Association), GLP-1 Receptor Agonists and the Risk of Thyroid Cancer, November 2022 Frontiers in Endocrinology, Effects of GLP-1 Agonists and SGLT2 Inhibitors During Pregnancy and Lactation on Offspring Outcomes: A Systematic Review of the Evidence, October 2023 UCLA Health, Semaglutide for Weight Loss - What You Need to Know US Food and Drug Administration, FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss UT Southwestern Medical Center, 4 Factors That Can Decrease Breast Milk Supplyand How to Replenish It, May 2022 Real-parent perspectives: Kelley D., mom of two in Indiana Learn how we ensure the accuracy of our content through our editorial and medical review process
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
See all conditions we support Supportive wellness care under physician supervision
This is not necessarily true, especially if youre trying to prevent nausea
